Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Goodwill & Intangibles (2016 - 2022)

Historic Goodwill & Intangibles for Abeona Therapeutics (ABEO) over the last 11 years, with Q3 2022 value amounting to $2.2 million.

  • Abeona Therapeutics' Goodwill & Intangibles fell 9377.27% to $2.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $2.2 million, marking a year-over-year decrease of 9377.27%. This contributed to the annual value of $2.2 million for FY2021, which is 9377.89% down from last year.
  • Abeona Therapeutics' Goodwill & Intangibles amounted to $2.2 million in Q3 2022, which was down 9377.27% from $2.2 million recorded in Q2 2022.
  • Over the past 5 years, Abeona Therapeutics' Goodwill & Intangibles peaked at $77.3 million during Q4 2018, and registered a low of $2.2 million during Q4 2021.
  • Its 5-year average for Goodwill & Intangibles is $36.8 million, with a median of $35.1 million in 2020.
  • Per our database at Business Quant, Abeona Therapeutics' Goodwill & Intangibles soared by 11218.07% in 2018 and then crashed by 9377.89% in 2021.
  • Over the past 5 years, Abeona Therapeutics' Goodwill & Intangibles (Quarter) stood at $77.3 million in 2018, then decreased by 2.91% to $75.1 million in 2019, then crashed by 53.84% to $34.7 million in 2020, then plummeted by 93.78% to $2.2 million in 2021, then changed by 0.0% to $2.2 million in 2022.
  • Its Goodwill & Intangibles stands at $2.2 million for Q3 2022, versus $2.2 million for Q2 2022 and $2.2 million for Q1 2022.